T
he clinical syndrome of heart failure with preserved ejection fraction (HFpEF) is characterized broadly by signs and symptoms of heart failure and in the absence of a reduced left ventricular ejection fraction. 1 Precise definition and diagnostic clinical criteria for HFpEF remain controversial but, for the purposes of inclusion in clinical trials, have become more stringent in recent years because of concerns about enrolling patients with other causes of dyspnea and edema misdiagnosed as heart failure. 2 The PARAGON-HF trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in Heart Failure and Preserved Left Ventricular Ejection Fraction) is a large, double-blind randomized controlled clinical outcomes trial testing the hypothesis that sacubitril/valsartan, an angiotensin receptor neprilysin inhibitor would be superior to valsartan in reducing morbidity and mortality in patients with HFpEF. 3 Sacubitril/valsartan simultaneously blocks the angiotensin II type I receptor and inhibits the enzyme neprilysin, a protease that plays a role in the breakdown of several vasoactive peptides, including the biologically active natriuretic peptides. Compared with enalapril, sacubitril/valsartan conclusively reduced morbidity and mortality among patients with heart failure with reduced ejection fraction (HFrEF) in PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure). 4 In a phase II trial of HFpEF, PARAMOUNT-HF (Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction), 5 sacubitril/valsartan compared with valsartan, reduced NT-proBNP (N-terminal pro-B-type natriuretic peptide) at 12 weeks and reduced both left atrial volume and New York Heart Association (NYHA) class at 36 weeks compared with valsartan. 4 These data provided the rationale for the design of PARAGON-HF, which was also heavily influenced by the experience gained from previous trials of HFpEF. In this report, we describe the baseline characteristics of patients enrolled in PARAGON-HF and compare them to patients enrolled in other clinical trials of patients with HFpEF and with the recently completed PARADIGM-HF trial.
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Patients and Study Design
PARAGON-HF is a randomized, double-blind, parallel group, active-controlled, 2-arm event-driven trial comparing the efficacy and safety of sacubitril/valsartan versus valsartan in patients with HFpEF. PARAGON-HF enrolled patients with signs and symptoms of heart failure (NYHA class II-IV), left ventricular ejection fraction of ≥45, increased plasma concentrations of NT-proBNP (degree of elevation depending on history of heart failure hospitalization within 9 months and presence or absence of atrial fibrillation), and evidence of structural heart disease (increased left atrial size or left ventricular hypertrophy). Before randomization, patients entered sequential single-blind run-in periods ensuring that both treatments were tolerated at half the target doses. The primary end point for the trial is cardiovascular death and total number of (first and recurrent) heart failure hospitalizations. The trial is event-driven and will stop when at least 1847 primary events are reached. The study was approved by institutional review boards at individual study sites, and all patients signed written informed consent. The details of the study design are published. 3 Baseline characteristics were collected at screening, and several of these were assessed again at randomization. We report baseline characteristics at screening for all variables unless otherwise stated, as screening represents a truer baseline because of the sequential run-in periods before randomization. Because plasma concentrations of NT-proBNP required for enrollment in PARAGON-HF differed based on the presence or absence of atrial fibrillation (AF) at screening, and whether or not patients had been hospitalized for heart failure within 9 months, we grouped baseline characteristics based on these measures. In addition, we grouped baseline characteristics based on region of origin: Asia-Pacific/Other, Central Europe, Latin America, North America, or Western Europe. Finally, we compared baseline characteristics from PARAGON-HF with those of other HFpEF trials, including those patients enrolled
WHAT IS NEW?
• This is a contemporary description of an international cohort of patients with heart failure and preserved ejection fraction in a large clinical trial, 
WHAT ARE THE CLINICAL IMPLICATIONS?
• Patients with heart failure with preserved ejection fraction are at substantially increased risk of morbidity and mortality.
• These data provide insight into the clinical characteristics of patients with heart failure with preserved ejection fraction, stringently defined by the entry criteria of the PARAGON-HF trial.
• These data will serve as a detailed description of the baseline characteristics of this trial that allow for comparison to other cohorts, including realworld cohorts and registries of patients with heart failure with preserved ejection fraction.
in the Americas in TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist), 6 I-PRESERVE (Irbesartan in Heart Failure With Preserved Ejection Fraction), 7 CHARM-Preserved (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity), 8 and PEP-CHF (Perindopril in Elderly People With Chronic Heart Failure), 9 and with patients with HFrEF enrolled in the PARADIGM-HF trial. 4 Assessment in TOPCAT was confined to those patients enrolled in the Americas because of concern about enrollment of patients without clinical heart failure in those enrolled in Russia and the Republic of Georgia. 2 The MAGGIC (MetaAnalysis Global Group in Chronic Heart Failure) risk score, 10 a validated risk score in heart failure, was calculated. Baseline characteristics are compared using t tests or ANOVA for continuous variables and χ 2 test for categorical variables.
RESULTS
Between July 18, 2014, and December 16, 2016, 11 302 patients were screened for inclusion in the study in 43 countries. The most common reasons for screen failure were insufficient NT-proBNP (61%), elevated potassium (10%), estimated glomerular filtration rate below inclusion cutoff (6%), alternative diagnoses other than HFpEF (6%), and elevated liver function tests (4%). Five thousand seven hundred and fifty-four patients who fulfilled inclusion and exclusion criteria entered valsartan run-in, and of these, 544 did not complete the valsartan run-in phase. Subsequently, 5210 entered the sacubitril/valsartan run-in phase, and of these, 388 did not complete the sacubitril/valsartan run-in phase. The most common reasons for run-in failure were predefined safety adverse events (65%) including predefined safety criteria for blood pressure, serum potassium, and renal function, subject decision (15%), protocol deviation (12%), noncompliance (5%), and death (2%). Ultimately, 4822 patients were randomized to sacubitril/valsartan or valsartan. Baseline characteristics of randomized patients are shown in Table 1 , and signs and symptoms of heart failure in randomized patients are shown in Figure. Their median age was 73±8.4 years, 52% were women, most were in NYHA functional class II, and the mean left ventricular ejection fraction was 58±7.9%. Only 48% of patients had had a prior heart failure hospitalization and of these almost 80% had been in the previous 9 months. Nearly all (98%) patients had dyspnea on effort, and many had fatigue (59%), edema (45%), orthopnea (22%), jugular venous distension (17%), rales (11%), paroxysmal nocturnal dyspnea (7.6%), and dyspnea at rest (4.6%). AF or flutter (32%) based on an ECG at the time of screening, diabetes mellitus (43%), and chronic kidney disease (47%) were all common. As required by the protocol, almost all patients were on diuretics and had structural heart disease, including left atrial enlargement in 99.6%, at screening. ACE (angiotensin-converting enzyme) inhibitors or angiotensin receptor blocker (ARB) (85%), β-blocker (80%), and mineralocorticoid receptor antagonist (27%) were commonly prescribed. The median MAGGIC risk score was 20 (interquartile range, 16-24).
Patients who fulfilled inclusion criteria, entered runin, but were not randomized, were slightly older, were slightly higher NYHA class, had lower systolic blood pressure, were more likely to have been hospitalized for heart failure, had higher NT-proBNP, lower estimated glomerular filtration rate, and had less use of ACE inhibitors, ARBs, and β-blockers (Table 1) .
Patients with AF (Table I in the Data Supplement) were older, more likely to be men, and had features suggesting more advanced heart failure, such as worse NYHA class, higher heart rate and lower blood pressure, substantially higher plasma concentrations of NT-proBNP (per protocol requirement), and MAGGIC risk score. Patients with a history of hospitalization for heart failure within the previous 9 months (Table II in the Data Supplement) were younger, had higher NYHA class and were more likely to be prescribed mineralocorticoid receptor antagonists (MRAs) but had lower plasma concentrations of NT-proBNP (reflecting the lower threshold required for inclusion), and the MAG-GIC risk score was slightly, but significantly, lower.
Patients in North America and Western Europe tended to be older (Table III in the Data Supplement) , and more likely to have AF. North Americans were mostly likely to have diabetes mellitus; BMI was highest in North America and lowest in Asia. There were substantial differences in concomitant therapy by region. MRA use was nearly twice as high in Asia as in other regions. Although ACE inhibitor or ARB use was similar overall between regions, the proportion of ACE inhibitor to ARB varied widely. Nitrate use was highest in North America, and anticoagulant use was highest in Western Europe. The MAGGIC risk score was lowest in Central Europe and highest in North America and Western Europe.
In comparison with other trials of HFpEF (Table 2) , patients enrolled in PARAGON-HF were of similar age, with the exception of CHARM-Preserved, which allowed inclusion of younger patients. More patients were in NYHA class II compared with previous trials. Entry blood pressure was similar to that in other trials except TOPCATAmericas, which required patients to have systolic blood pressure <130 mm Hg at entry, and PEP-CHF, in which blood pressure was higher. Left ventricular ejection fraction was similar to prior trials except for PEP-CHF, in which it was higher. The prevalence of diabetes mellitus and chronic kidney disease were similar to that observed in TOPCAT-Americas but higher than in other trials.
Characteristics differed substantially from patients with HFrEF enrolled in PARADIGM-HF (Table IV in were more likely to be prescribed an ARB rather than an ACE inhibitor before screening, but overall use of either an ACE inhibitor or ARB was similar. Prescription of β-blockers was similar in the two trials, but patients in PARAGON-HF were much less likely to be prescribed an MRA. The overall MAGGIC risk score for mortality was similar for PARAGON-HF and PARADIGM-HF.
DISCUSSION
PARAGON-HF is the most contemporary and largest outcomes trial for HFpEF conducted to date, with more stringent entry criteria than previous trials. The baseline characteristics of patients enrolled in PARAGON-HF are generally consistent with those in prior trials of HFpEF, Figure. Heart failure signs and symptoms in enrolled patients. ACE indicates angiotensin-converting enzyme; ADP, adenosin diphosphate; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HHF, hospitalization for heart failure; IQR, interquartile range; LA, left atrial; MAGGIC, MetaAnalysis Global Group in Chronic Heart Failure; n/a, data not available; and NYHA, New York Heart Association. although are reflective of the somewhat more stringent inclusion criteria than in prior trials, designed to exclude low-risk patients who might have little to gain from a novel intervention and to include patients with a higher rate of events. Similar to other HFpEF trials and epidemiological studies, those enrolled in PARAGON-HF were, on average, older than patients enrolled in trials of HFrEF, and included a much higher proportion of women. The prevalence of comorbidities was high, including prior hypertension, diabetes mellitus, coronary artery disease, and AF. Despite capping enrollment of patients with AF, 32% had atrial fibrillation at enrollment and more than half had a history of AF, suggesting that paroxysmal AF is extremely common in HFpEF.
All patients enrolled in PARAGON-HF after protocol amendment 2 were required to have increased plasma concentration of NT-proBNP, with thresholds based on whether or not they had AF at screening and whether or not they had been hospitalized for heart failure within the prior 9 months. Before this amendment, which occurred early during the course of recruitment, patients could be enrolled without an increased NTproBNP if they had been hospitalized in the previous 9 months. After the amendment, patients were required to have NT-proBNP >200 pg/mL if in sinus rhythm or >600 pg/mL if in AF, if they had been hospitalized; if they had not been hospitalized for heart failure in the previous 9 months, they were required to have an NTproBNP >300 pg/mL if in sinus rhythm, and >900 pg/ mL if in AF. Only 136 patients (<3%) were enrolled who did not fulfill these NT-proBNP criteria. Because patients enrolled with a history of HF hospitalization could be included with a lower NT-proBNP, on average, the NT-proBNP and risk profile for this group was slightly lower than those in the subgroup that had not been hospitalized.
Patients who fulfilled PARAGON-HF inclusion criteria and entered run-in but were not randomized were slightly older, sicker, and more comorbid than patients who were randomized. Not surprisingly, the most frequent reasons for failing run-in were adverse events, such as hypotension, hyperkalemia, and renal dysfunction per protocol-defined safety criteria, which would be expected to be more likely in a frailer population. The run-in was designed to maximize adherence to study medication during the double-blind period, but ultimately excludes some patients who may have trouble tolerating the therapy at target doses.
In general, patients with AF were more likely to have other characteristics suggestive of higher risk, and their MAGGIC risk scores were higher. The NT-proBNP requirement was tripled for patients with AF to avoid the criticism that increased NT-proBNP reflected AF rather than heart failure. Although some risk factors were less prominent in patients who had had a heart failure hospitalization within 9 months, this was likely because of the fact that these patients had a lower NT-proBNP. Nevertheless, prior analyses suggest that these groups should carry a similar risk of events, 11 and patients with both atrial fibrillation and elevation in NTproBNP are likely to be at higher overall risk. Importantly, despite strong recommendations in guidelines <60% of patients with AF were reported to be treated with anticoagulants, which may reflect strong regional differences in the use of anticoagulants in this population.
Regional differences in characteristics of patients with HFpEF have been noted previously. 12 Patients in Central Europe were slightly younger and tended to have less renal dysfunction and lower NT-proBNP than in other regions. There were some substantial differences in concomitant medication use by region. Patients in North America and Western Europe were less likely to use MRAs than other regions. ACE inhibitor use was particularly low in Asia. Overall those in Central Europe had the lowest MAGGIC risk scores, and those in North America and Western Europe had the highest risk scores.
Differences in baseline characteristics between patients enrolled in PARAGON-HF and those enrolled in prior HFpEF trials, such as the higher prevalence of diabetes mellitus and renal dysfunction, may be, to some extent, a result of the more stringent entry criteria in PARAGON-HF, which required patients to have an increase in NT-proBNP and evidence of structural heart disease or may reflect differ- ent regional distribution, including more patients enrolled in the United States. Diagnostic awareness and thresholds for renal dysfunction and diabetes mellitus may also have changed. The MAGGIC risk score, a well-validated comprehensive measure of mortality risk in heart failure, was similar to that observed in TOPCAT-Americas and slightly higher than that observed in CHARM-Preserved. Interestingly, the PARAGON-HF MAGGIC risk score was similar to that observed in PARADIGM-HF, a trial of HFrEF, probably because of the greater average age of participants in PARAGON-HF. MRA use was higher than in previous trials, which may be a result of the TOPCAT trial which showed relatively favorable results for spironolactone or may reflect inclusion of more Asian patients, in whom MRA use was especially high (40%). Guidelines recommend that patients with HFrEF should generally receive an ACE inhibitor, an ARB or an ARNI, a β-blocker, and an MRA and indicate that there is no robust evidence that any of these agents is effective for patients with HFpEF. Accordingly, it might be thought that large differences in treatment patterns would be observed between HFrEF and HFpEF, yet the similarities seem as striking as the differences, an observation that has also been observed in registries. 13 This might reflect a failure to distinguish among phenotypes in clinical practice, or the use of these agents to treat comorbid conditions, such as hypertension, ischemic heart disease, or atrial fibrillation.
In summary, PARAGON-HF is the largest clinical outcomes trial in HFpEF conducted to date. Patient characteristics are largely similar to those enrolled in other HFpEF trials, and in HFpEF epidemiological cohorts, although some differences in characteristics likely are because of the more stringent enrollment criteria in PARAGON-HF than prior trials, as well as some clear regional differences. PARAGON-HF will determine whether sacubitril/valsartan, which has previously been shown to benefit patients with HFrEF, will also reduce morbidity and mortality in HFpEF.
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